您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Vinorelbine ditartrate(KW-2307)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Vinorelbine ditartrate(KW-2307)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Vinorelbine ditartrate(KW-2307)图片
CAS NO:125317-39-7
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议
1g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)1079.11
FormulaC45H54N4O8.2C4H6O6
CAS No.125317-39-7
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 100 mg/mL (92.7 mM)
Water: 100 mg/mL (92.7 mM)
Ethanol: 100 mg/mL (92.7 mM)
Other info

Chemical Name: methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis((2R,3R)-2,3-dihydroxysuccinate)

InChi Key: CILBMBUYJCWATM-PYGJLNRPSA-N

InChi Code: InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t28-,37-,38+,39+,42+,43+,44-,45-;2*1-,2-/m011/s1

SMILES Code: O=C(OC)[C@@]1([C@@]2(N(C3=C([C@@]24CCN5CC=C[C@@](CC)([C@H]1OC(C)=O)[C@@]45[H])C=C(C(OC)=C3)[C@]6(C[C@]7([H])C=C(CN(CC8=C6NC9=C8C=CC=C9)C7)CC)C(OC)=O)C)[H])O.O=C([C@@H]([C@H](C(O)=O)O)O)O.O=C([C@@H]([C@H](C(O)=O)O)O)O

Synonyms

KW2307, Nor-5'-anhydrovinblastine ditartrate, vinorelbine tartrate, KW-2307, KW 2307, Navelbine, Biovelbin, Eunades

实验参考方法
In Vitro

In vitro activity: Vinorelbine inhibits microtubule assembly by inducing tubulin aggregation into spirals and paracrystals. Vinorelbine shows potent antiproliferative activity against a series of tumor cells, including human melanoma, non-small-cell lung cancer, breast cancer, etc.

In VivoIn vivo, Vinorelbine also shows antitumour activity against a series of subcutaneously-implanted human tumour xenografts.
Animal modelBladder (BXF1299), pancreas (PAXF546), kidney (RXF944LX), colon (DLD-1, HT-29, TC37), central nervous system (SF-295), small cell lung (NCI-H69) and prostate (PC-3) xenografts.
Formulation & DosageDissolved in Sterile 0.9% sodium chloride solution; 10 mg/kg; i.p. injection
References

Semin Oncol. 1989 Apr;16(2 Suppl 4):9-14; Eur J Cancer. 1999 Mar;35(3):512-20.